



## **EVITRADE Announces Mutual Termination of Previously Contemplated Transaction with Cantech Molecular Research Inc.**

VANCOUVER, BC, January 23, 2019 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the “Company” or “Evitrade”) hereby announces that effective January 22, 2019 it has mutually terminated the previously announced contemplated transaction and underlying agreement with Cantech Molecular Research Inc. (“Cantech”)

Management of Evitrade believe that the contemplated transaction was no longer in line with the business and commercialization strategies of the Company leading to the mutual termination of the same by the parties.

***For more information, please contact:***

Sydney Au, Director  
EVITRADE Health Systems Corporation  
(formerly Auxellence Health Corporation)  
Email [info@evahealthsystems.com](mailto:info@evahealthsystems.com)  
Website <http://www.evahealthsystems.com>  
CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp> US OTC  
Markets (OTCQB): <http://www.otcmarkets.com/stock/EVAHF/news>

**About EVITRADE Health (CSE: EVA, OTCQB: EVAHF)**

*EVITRADE Health Systems Corp. (formerly Auxellence Health Corp.), is a Technology company specializing in the Life Sciences sector looking to deliver effective health solutions with a higher degree of predictability and consistency. The Company is focused in four main areas, Autonomous Medical Care, Molecular Biology, Nutraceutical Solutions and Genetic Selection. Through its Focus on Autonomous Medical Care, the Company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for hypertension, arrhythmia, diabetes, and obesity.*

**Disclaimers**

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.